Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories forecasted Annual Intangible Amortization — Year 5 ($M) ($M)
Form 10-K / 10-Q Goodwill & Intangibles Footnote
Latest, Q4 2025
363
Period ended Dec 31, 2025
Change on a year earlier
-40.0%
605 in Q4 2024
History
36 quarters
Since Q1 2013
Sources
25
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Forecasted Annual Intangible Amortization — Year 5 ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | 363 | -40.0% | SEC Filing (0001628280-26-010185) ↗ |
| Q4 2024 | Dec 31, 2024 | 605 | -13.6% | SEC Filing (0001628280-25-007110) ↗ |
| Q4 2023 | Dec 31, 2023 | 700 | -41.7% | SEC Filing (0001628280-24-005348) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,200 | -25.0% | SEC Filing (0001628280-23-004026) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,600 | -15.8% | SEC Filing (0001104659-22-025141) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,900 | 0.0% | SEC Filing (0001104659-21-025751) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,900 | -5.0% | SEC Filing (0001104659-20-087850) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,900 | -5.0% | SEC Filing (0001104659-20-053384) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,900 | -5.0% | SEC Filing (0001104659-20-023904) ↗ |
| Q3 2019 | Sep 30, 2019 | 2,000 | 0.0% | SEC Filing (0001104659-19-058323) ↗ |
| Q2 2019 | Jun 30, 2019 | 2,000 | 0.0% | SEC Filing (0001410578-19-000606) ↗ |
| Q1 2019 | Mar 31, 2019 | 2,000 | 0.0% | SEC Filing (0001104659-19-026018) ↗ |
| Q4 2018 | Dec 31, 2018 | 2,000 | 0.0% | SEC Filing (0001047469-19-000624) ↗ |
| Q3 2018 | Sep 30, 2018 | 2,000 | +11.1% | SEC Filing (0001104659-18-065076) ↗ |
| Q2 2018 | Jun 30, 2018 | 2,000 | +17.6% | SEC Filing (0001104659-18-048736) ↗ |
| Q1 2018 | Mar 31, 2018 | 2,000 | 0.0% | SEC Filing (0001104659-18-029831) ↗ |
| Q4 2017 | Dec 31, 2017 | 2,000 | +455.6% | SEC Filing (0001047469-18-000856) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,800 | +339.0% | SEC Filing (0001104659-17-065654) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,700 | +254.2% | SEC Filing (0001104659-17-048855) ↗ |
| Q1 2017 | Mar 31, 2017 | 2,000 | +316.7% | SEC Filing (0001104659-17-029430) ↗ |
| Q4 2016 | Dec 31, 2016 | 360 | -25.0% | SEC Filing (0001047469-17-000744) ↗ |
| Q3 2016 | Sep 30, 2016 | 410 | -22.6% | sec_companyfacts ↗ |
| Q2 2016 | Jun 30, 2016 | 480 | -9.4% | sec_companyfacts ↗ |
| Q1 2016 | Mar 31, 2016 | 480 | -9.4% | sec_companyfacts ↗ |
| Q4 2015 | Dec 31, 2015 | 480 | -0.8% | SEC Filing (0001047469-16-010246) ↗ |
| Q3 2015 | Sep 30, 2015 | 530 | +1.9% | sec_companyfacts ↗ |
| Q2 2015 | Jun 30, 2015 | 530 | +6.0% | sec_companyfacts ↗ |
| Q1 2015 | Mar 31, 2015 | 530 | +6.0% | sec_companyfacts ↗ |
| Q4 2014 | Dec 31, 2014 | 484 | -4.2% | SEC Filing (0001047469-15-001377) ↗ |
| Q3 2014 | Sep 30, 2014 | 520 | -11.1% | sec_companyfacts ↗ |
| Q2 2014 | Jun 30, 2014 | 500 | -8.3% | sec_companyfacts ↗ |
| Q1 2014 | Mar 31, 2014 | 500 | -8.3% | sec_companyfacts ↗ |
| Q4 2013 | Dec 31, 2013 | 505 | – | SEC Filing (0001047469-14-001176) ↗ |
| Q3 2013 | Sep 30, 2013 | 585 | – | sec_companyfacts ↗ |
| Q2 2013 | Jun 30, 2013 | 545 | – | sec_companyfacts ↗ |
| Q1 2013 | Mar 31, 2013 | 545 | – | sec_companyfacts ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Forecasted Annual Intangible Amortization — Year 5 ($M) ($M), quarterly Q1 2013–Q4 2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/intang-amort-y5
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.